On this page
Methylmalonic acidaemia (MUT)
This condition is caused by changes in the MUT gene and typically presents in infancy or early childhood. It can lead to severe health issues if not managed, affecting an individual's growth and neurological development. Early diagnosis is important for better outcomes.
Available at Jeen Health
Clinical tests that include this
Overview
Methylmalonic acidaemia (MUT) is an inherited metabolic condition where the body struggles to break down certain proteins and fats. Specifically, it affects the metabolism of particular amino acids (building blocks of protein) and fatty acids [PMID:33600109]. This difficulty in processing leads to an accumulation of methylmalonic acid and other toxic substances in the body, which can become harmful.
This condition is classified as an inborn error of metabolism, meaning it's present from birth due to a genetic change. While it is considered rare, affecting approximately 1 in 50,000 newborns, its exact prevalence may vary across different populations [PMID:32590209].
Symptoms & clinical features
The symptoms of methylmalonic acidaemia (MUT) can vary in severity and when they first appear. In many cases, symptoms begin in infancy, often within the first few months of life. Affected infants may experience poor feeding, vomiting, reduced muscle tone (hypotonia), and lethargy.
As the condition progresses, more severe symptoms can develop, including developmental delay, seizures, and a failure to thrive. Without timely diagnosis and management, there can be life-threatening metabolic crises, which are episodes of extreme illness caused by the build-up of toxic substances. In some rarer instances, individuals may develop a later-onset form of the condition with milder symptoms or even be asymptomatic for a longer period.
Video: Genetics 101
Affected organs
Methylmalonic acidaemia (MUT) can affect multiple organ systems due to the widespread build-up of toxic metabolites. The brain and nervous system are particularly vulnerable, leading to neurological complications such as developmental delay, intellectual disability, and movement problems.
The kidneys can also be affected, sometimes resulting in kidney disease. Other organs like the liver and heart may show signs of involvement, particularly during metabolic crises. The bone marrow can also be impacted, leading to anaemia or a reduced number of white blood cells.
Risks & severity
The severity of methylmalonic acidaemia (MUT) varies significantly among individuals, ranging from severe, life-threatening forms in infancy to milder forms that may present later in childhood or even adulthood. The most severe cases often involve significant neurological damage and frequent metabolic crises if not carefully managed from an early age.
Long-term risks include progressive kidney disease, chronic neurological impairment, and growth problems. Early diagnosis and consistent management, including dietary restrictions and supplementation, are crucial for improving outcomes and reducing the risk of severe complications. However, even with optimal management, some individuals may still experience lifelong health challenges.
Genetic causes
Methylmalonic acidaemia (MUT) is caused by genetic changes in the MUT gene. This gene provides instructions for making an enzyme called methylmalonyl-CoA mutase. This enzyme plays a critical role in the metabolic pathway that breaks down certain amino acids (like isoleucine, valine, methionine, and threonine) and odd-chain fatty acids [PMID:32590209].
When there are pathogenic changes in the MUT gene, the methylmalonyl-CoA mutase enzyme either doesn't work correctly or isn't produced in sufficient quantities. This enzyme deficiency prevents the proper conversion of methylmalonyl-CoA to succinyl-CoA. As a result, methylmalonyl-CoA and related compounds, including methylmalonic acid, accumulate to toxic levels in the body, leading to the symptoms of the condition [PMID:33600109].
- MUT methylmalonyl-CoA mutase
Inheritance pattern
Methylmalonic acidaemia (MUT) is inherited in an autosomal recessive pattern. This means that a child must inherit two copies of a changed MUT gene - one from each parent - to develop the condition. Individuals who inherit only one copy of the changed gene are called carriers.
Carriers typically do not show any symptoms of methylmalonic acidaemia (MUT) themselves, but they can pass the changed gene on to their children. If both parents are carriers of a changed MUT gene, there is a 1 in 4 (25%) chance with each pregnancy that their child will inherit two changed copies and develop the condition. There is also a 1 in 2 (50%) chance that the child will be a carrier, and a 1 in 4 (25%) chance that the child will not inherit any changed copies of the gene.
When both parents are carriers, each child has a 25% chance of being affected, 50% of being a carrier, and 25% of being unaffected.
Diagnosis & testing
Diagnosis of methylmalonic acidaemia (MUT) often begins with newborn screening in the UK, which can detect elevated levels of methylmalonic acid or related markers in blood spots. If screening results are abnormal, further investigations are required to confirm the diagnosis.
Confirmatory diagnostic testing typically involves specialised biochemical tests on blood and urine samples to measure the levels of methylmalonic acid and other metabolites. Genetic testing, specifically looking for changes in the MUT gene, is used to confirm the diagnosis and identify the exact genetic cause. Referrals for genetic testing are usually made by a paediatrician or a metabolic specialist through the NHS Genomic Medicine Service, often guided by R-codes such as R14 (Rare and Inherited Disease) or R15 (Metabolic Disorders) in England.
Management & lifestyle
The management of methylmalonic acidaemia (MUT) focuses on reducing the build-up of toxic metabolites and preventing metabolic crises. This primarily involves strict dietary management, often with a low-protein diet tailored to the individual's needs, limiting the intake of amino acids that cannot be processed [PMID:33600109]. Special medical foods and formulas may be used to provide adequate nutrition.
Some individuals may benefit from vitamin B12 (cobalamin) supplementation, as certain forms of methylmalonic acidaemia are responsive to this vitamin. Regular monitoring of metabolic markers in blood and urine is essential to adjust treatment as needed. In the UK, care is typically provided by specialist metabolic teams within the NHS, including dietitians, paediatricians, and genetic counsellors, who can provide ongoing support and guidance.
UK care pathway
In the UK, individuals suspected of having an inherited metabolic condition like methylmalonic acidaemia (MUT) would typically be referred through their GP or paediatrician to a specialist metabolic centre. These centres are part of the NHS Genomic Medicine Service and provide expert diagnosis and management.
Genetic testing is often requested by a clinical geneticist or metabolic specialist and processed via the NHS Genomic Laboratory Networks, using relevant R-codes for rare and inherited diseases. Genetic counsellors play a vital role in explaining the condition, inheritance patterns, and implications for families.
Frequently asked questions
What is a metabolic crisis?
A metabolic crisis is a severe episode of illness that can occur in individuals with methylmalonic acidaemia (MUT). It happens when toxic substances build up rapidly in the body, often triggered by illness, infection, or not following the dietary plan. Symptoms can include severe vomiting, lethargy, confusion, and can be life-threatening.
Can methylmalonic acidaemia (MUT) be cured?
Currently, there is no cure for methylmalonic acidaemia (MUT). However, the condition can be managed effectively with a combination of strict dietary control, medication, and close medical supervision. Early diagnosis and consistent management can significantly improve long-term health outcomes and quality of life.
How does diet affect methylmalonic acidaemia (MUT)?
Diet plays a central role in managing methylmalonic acidaemia (MUT). A special low-protein diet is usually required to limit the intake of amino acids that the body cannot properly break down. This helps to prevent the build-up of harmful substances. Dietary plans are highly individualised and managed by specialist dietitians.
What support is available for families in the UK?
In the UK, families affected by methylmalonic acidaemia (MUT) can access support through NHS specialist metabolic centres, which include metabolic consultants, dietitians, and genetic counsellors. Patient organisations and charities also offer resources, information, and peer support for individuals and their families living with inherited metabolic conditions.
Is newborn screening available for this condition in the UK?
Yes, methylmalonic acidaemia (MUT) is included in the UK Newborn Blood Spot Screening Programme. This means that all babies born in the UK are offered a screening test a few days after birth to detect the condition early, allowing for prompt diagnosis and management.